Bevacizumab biosimilar (Outlook)

贝伐珠单抗生物类似药 (Outlook)

Report date: 2026/03/09 20:02:04

Base Information

Drug NameBevacizumab biosimilar (Outlook)
Drug Alias Namebevacizumab-vikgbevacizumab gammaLytenavaONS-5010ONS-1045
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionAngiogenesis inhibitorsVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsDiabetic macular oedemaRetinal Vein OcclusionWet age-related macular degeneration +[4] 
Global Approved IndicationsWet age-related macular degeneration
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2024/05/27
Country/TerritoryUnited StatesAustraliaEU +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesOutlook Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesOutlook Therapeutics LtdBeijing Syntone Biopharma LtdOutlook Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaRetinal Vein OcclusionWet age-related macular degeneration
Inactive IndicationsMacular Degeneration

Other Information

ATC CodeS01LA08
Related LinksN/A